Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- Author
- ERON, Joseph1 ; ROCKSTROH, Jürgen K2 ; NELSON, Mark11 ; CAMPBELL, Havilland12 ; JING ZHAO12 ; RODGERS, Anthony J12 ; RIZK, Matthew L12 ; WENNING, Larissa12 ; MILLER, Michael D12 ; HAZUDA, Daria12 ; DINUBILE, Mark J12 ; LEAVITT, Randi12 ; REYNES, Jacques3 ; ISAACS, Robin12 ; ROBERTSON, Michael N12 ; SKLAR, Peter12 ; NGUYEN, Bach-Yen12 ; ANDRADE-VILLANUEVA, Jaime4 ; RAMALHO-MADRUGA, Jose Valdez5 ; BEKKER, Linda-Gail6 ; YOUNG, Benjamin7 ; KATLAMA, Christine8 ; GATELL-ARTIGAS, Jose Maria9 ; ARRIBAS, Jose R10
[1] University of North Carolina School of Medicine, Chapel Hill, NC, United States
[2] Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany
[3] Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France
[4] Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico
[5] Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil
[6] University of Cape Town, Cape Town, South Africa
[7] Rocky Mountain CARES/Denver Infectious Disease Consultants, Denver, CO, United States
[8] Hôpital Pitié-Salpêtrière, Paris, France
[9] Hospital Clinic I Provincial de Barcelona, Barcelona, Spain
[10] Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain
[11] St Stephen's AIDSTrust/ Crusaid Research Institute, London, United Kingdom
[12] Merck Research Laboratories, North Wales, PA, United States
QDMRK Investigators - Source
Lancet. Infectious diseases (print). 2011, Vol 11, Num 12, pp 907-915, 9 p ; ref : 28 ref
- ISSN
- 1473-3099
- Scientific domain
- General medicine general surgery; Microbiology, infectious diseases
- Publisher
- Lancet Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antirétroviral Antiviral Homme Raltégravir SIDA Virus HIV1 Inhibiteur de transfert de brins Immunodéficit Immunopathologie Infection Inhibiteur de l'intégrase Lentivirus Retroviridae Virose Virus immunodéficience humaine Virus
- Keyword (en)
- Antiretroviral agent Antiviral Human Raltegravir AIDS HIV-1 virus Immune deficiency Immunopathology Infection Integrase inhibitor Lentivirus Retroviridae Viral disease Human immunodeficiency virus Virus
- Keyword (es)
- Antiretroviral Antiviral Hombre Raltegravir SIDA HIV-1 virus Inmunodeficiencia Inmunopatología Infección Inhibidor integrase Lentivirus Retroviridae Virosis Human immunodeficiency virus Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D01 Immunodeficiencies
- Discipline
- Immunopathology Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 25232519
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S1473-3099(11)70196-7 
https://dx.doi.org/10.1016/S1473-3099(11)70196-7
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(11)70196-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:3:\"907\";s:8:\"\u0000*\u0000epage\";s:3:\"915\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joseph\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:20:\"ROCKSTROH, J\u00fcrgen K\";i:1;s:12:\"NELSON, Mark\";i:2;s:19:\"CAMPBELL, Havilland\";i:3;s:9:\"JING ZHAO\";i:4;s:18:\"RODGERS, Anthony J\";i:5;s:15:\"RIZK, Matthew L\";i:6;s:16:\"WENNING, Larissa\";i:7;s:17:\"MILLER, Michael D\";i:8;s:13:\"HAZUDA, Daria\";i:9;s:16:\"DINUBILE, Mark J\";i:10;s:14:\"LEAVITT, Randi\";i:11;s:15:\"REYNES, Jacques\";i:12;s:13:\"ISAACS, Robin\";i:13;s:20:\"ROBERTSON, Michael N\";i:14;s:12:\"SKLAR, Peter\";i:15;s:16:\"NGUYEN, Bach-Yen\";i:16;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:17;s:28:\"RAMALHO-MADRUGA, Jose Valdez\";i:18;s:18:\"BEKKER, Linda-Gail\";i:19;s:15:\"YOUNG, Benjamin\";i:20;s:18:\"KATLAMA, Christine\";i:21;s:26:\"GATELL-ARTIGAS, Jose Maria\";i:22;s:15:\"ARRIBAS, Jose R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(11)70196-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:3:\"907\";s:8:\"\u0000*\u0000epage\";s:3:\"915\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joseph\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:20:\"ROCKSTROH, J\u00fcrgen K\";i:1;s:12:\"NELSON, Mark\";i:2;s:19:\"CAMPBELL, Havilland\";i:3;s:9:\"JING ZHAO\";i:4;s:18:\"RODGERS, Anthony J\";i:5;s:15:\"RIZK, Matthew L\";i:6;s:16:\"WENNING, Larissa\";i:7;s:17:\"MILLER, Michael D\";i:8;s:13:\"HAZUDA, Daria\";i:9;s:16:\"DINUBILE, Mark J\";i:10;s:14:\"LEAVITT, Randi\";i:11;s:15:\"REYNES, Jacques\";i:12;s:13:\"ISAACS, Robin\";i:13;s:20:\"ROBERTSON, Michael N\";i:14;s:12:\"SKLAR, Peter\";i:15;s:16:\"NGUYEN, Bach-Yen\";i:16;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:17;s:28:\"RAMALHO-MADRUGA, Jose Valdez\";i:18;s:18:\"BEKKER, Linda-Gail\";i:19;s:15:\"YOUNG, Benjamin\";i:20;s:18:\"KATLAMA, Christine\";i:21;s:26:\"GATELL-ARTIGAS, Jose Maria\";i:22;s:15:\"ARRIBAS, Jose R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(11)70196-7\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(11)70196-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:3:\"907\";s:8:\"\u0000*\u0000epage\";s:3:\"915\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joseph\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:20:\"ROCKSTROH, J\u00fcrgen K\";i:1;s:12:\"NELSON, Mark\";i:2;s:19:\"CAMPBELL, Havilland\";i:3;s:9:\"JING ZHAO\";i:4;s:18:\"RODGERS, Anthony J\";i:5;s:15:\"RIZK, Matthew L\";i:6;s:16:\"WENNING, Larissa\";i:7;s:17:\"MILLER, Michael D\";i:8;s:13:\"HAZUDA, Daria\";i:9;s:16:\"DINUBILE, Mark J\";i:10;s:14:\"LEAVITT, Randi\";i:11;s:15:\"REYNES, Jacques\";i:12;s:13:\"ISAACS, Robin\";i:13;s:20:\"ROBERTSON, Michael N\";i:14;s:12:\"SKLAR, Peter\";i:15;s:16:\"NGUYEN, Bach-Yen\";i:16;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:17;s:28:\"RAMALHO-MADRUGA, Jose Valdez\";i:18;s:18:\"BEKKER, Linda-Gail\";i:19;s:15:\"YOUNG, Benjamin\";i:20;s:18:\"KATLAMA, Christine\";i:21;s:26:\"GATELL-ARTIGAS, Jose Maria\";i:22;s:15:\"ARRIBAS, Jose R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(11)70196-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:3:\"907\";s:8:\"\u0000*\u0000epage\";s:3:\"915\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joseph\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:20:\"ROCKSTROH, J\u00fcrgen K\";i:1;s:12:\"NELSON, Mark\";i:2;s:19:\"CAMPBELL, Havilland\";i:3;s:9:\"JING ZHAO\";i:4;s:18:\"RODGERS, Anthony J\";i:5;s:15:\"RIZK, Matthew L\";i:6;s:16:\"WENNING, Larissa\";i:7;s:17:\"MILLER, Michael D\";i:8;s:13:\"HAZUDA, Daria\";i:9;s:16:\"DINUBILE, Mark J\";i:10;s:14:\"LEAVITT, Randi\";i:11;s:15:\"REYNES, Jacques\";i:12;s:13:\"ISAACS, Robin\";i:13;s:20:\"ROBERTSON, Michael N\";i:14;s:12:\"SKLAR, Peter\";i:15;s:16:\"NGUYEN, Bach-Yen\";i:16;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:17;s:28:\"RAMALHO-MADRUGA, Jose Valdez\";i:18;s:18:\"BEKKER, Linda-Gail\";i:19;s:15:\"YOUNG, Benjamin\";i:20;s:18:\"KATLAMA, Christine\";i:21;s:26:\"GATELL-ARTIGAS, Jose Maria\";i:22;s:15:\"ARRIBAS, Jose R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(11)70196-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:3:\"907\";s:8:\"\u0000*\u0000epage\";s:3:\"915\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ERON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Joseph\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:20:\"ROCKSTROH, J\u00fcrgen K\";i:1;s:12:\"NELSON, Mark\";i:2;s:19:\"CAMPBELL, Havilland\";i:3;s:9:\"JING ZHAO\";i:4;s:18:\"RODGERS, Anthony J\";i:5;s:15:\"RIZK, Matthew L\";i:6;s:16:\"WENNING, Larissa\";i:7;s:17:\"MILLER, Michael D\";i:8;s:13:\"HAZUDA, Daria\";i:9;s:16:\"DINUBILE, Mark J\";i:10;s:14:\"LEAVITT, Randi\";i:11;s:15:\"REYNES, Jacques\";i:12;s:13:\"ISAACS, Robin\";i:13;s:20:\"ROBERTSON, Michael N\";i:14;s:12:\"SKLAR, Peter\";i:15;s:16:\"NGUYEN, Bach-Yen\";i:16;s:25:\"ANDRADE-VILLANUEVA, Jaime\";i:17;s:28:\"RAMALHO-MADRUGA, Jose Valdez\";i:18;s:18:\"BEKKER, Linda-Gail\";i:19;s:15:\"YOUNG, Benjamin\";i:20;s:18:\"KATLAMA, Christine\";i:21;s:26:\"GATELL-ARTIGAS, Jose Maria\";i:22;s:15:\"ARRIBAS, Jose R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:145:\"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
